Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Down 15.3% in February

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) saw a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 75,300 shares, a drop of 15.3% from the February 13th total of 88,900 shares. Based on an average trading volume of 49,500 shares, the days-to-cover ratio is currently 1.5 days. Approximately 11.0% of the shares of the company are short sold.

Qualigen Therapeutics Trading Down 0.6 %

Qualigen Therapeutics stock traded down $0.02 during midday trading on Thursday, reaching $3.10. The stock had a trading volume of 1,325 shares, compared to its average volume of 99,184. Qualigen Therapeutics has a 12 month low of $2.96 and a 12 month high of $29.44. The firm’s 50-day moving average price is $3.50 and its 200 day moving average price is $5.17.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints.